RIFM cyclic and non-cyclic terpene alcohol assessment published
This article was originally published in The Rose Sheet
Executive Summary
Research Institute for Fragrance Materials publishes toxicologic and dermatologic assessment on cyclic and non-cyclic terpene alcohols, institute announces in a recent release. Assessment covers 68 materials, including linalool, geraniol and d,l-citronellol, among other high-priority fragrance materials. Group summary and fragrance material reviews show the substances are practically non-irritating, have a low sensitization potential and demonstrate no grounds for environmental concern at current levels of use, RIFM says. Terpene alcohol group summary is written by RIFM's expert panel while the fragrance material reviews are written by RIFM staff. Representing all toxicological data available to RIFM on the ingredients, the assessments are published in the November 2008 issue of Food and Chemical Toxicology. The institute plans to publish group summaries on alcohol branched chain unsaturated, alcohols branch chain saturated, benzaldehyde and its derivatives, and aryl alkyl alcohols. Seven group summaries and 182 fragrance material reviews have already been published; the summaries are used by industry to meet the requirements of the EU's Registration, Evaluation, Authorisation and Restriction of Chemical Substances program
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.